Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369529 | 0.90 | KLKB1 (0.48) | GSK3BKLKB1 | |
| SCHEMBL3359322 | 0.87 | KMT2A (0.46) | GSK3BKMT2AAADATKLKB1MEN1 | |
| SCHEMBL2506571 | 0.87 | GSK3B (0.42) | GSK3BKMT2AAADATKLKB1MEN1 | |
| SCHEMBL370507 | 0.86 | KMT2A (0.53) | KMT2AAADATKLKB1MEN1NPC1 | |
| SCHEMBL25198644 | 0.85 | GSK3B (0.47) | GSK3BKMT2AAADATKLKB1MEN1 | |
| SCHEMBL370325 | 0.85 | GSK3B (0.47) | GSK3BKMT2AAADATMEN1NPC1 | |
| SCHEMBL1046790 | 0.85 | GSK3B (0.47) | GSK3BKMT2AAADATKLKB1MEN1 | |
| SCHEMBL3356514 | 0.83 | MAPT (0.46) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL3356363 | 0.81 | GAA (0.51) | GSK3BKLKB1 | |
| SCHEMBL369065 | 0.81 | KLKB1 (0.46) | GSK3BKMT2AAADATKLKB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524718-B2 | Heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20120329811-A1 | Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2181110-A2 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009010455-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM4, GRM2 | GSK3B 1639/4885KMT2A 1716/4885AADAT 942/4885 |
| US-20120329811-A1 | Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | GRM3, GRM4, GRM1 | GSK3B 1530/4885KMT2A 1764/4885AADAT 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.